September 14, 2021 7:33am

The oversold are twinkling; shining with a gleam that changes from bright to faint.

Pre-open indications: BUY: 3; SELL: 1; Maintain SELL: 1

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Framing the main takeaway … pricing, volume and trading creates volatility and liquidity!

Dow futures are UP +0.01% (+5 points), S&P futures are UP +0.06% (+3 point) and NASDAQ futures are DOWN -0.01% (-2 point)


U.S. stock index futures are fluctuating in the “pre-teens” on Tuesday,

European markets pulled back slightly as global investors awaited inflation data from the U.S.,

Asia-Pacific markets were mixed as investors focused on tightening Chinese regulation for regional investors.


Data Docket: inflation data; economists are estimating consumer prices to have risen 0.4% month over month during August, and 5.4% year over year.



Yesterday, the Dow and S&P both advanced on Monday for the first time in six sessions as investors bet that some overbought looked sold on uncertainty of upcoming sessions – rest of week.

An interesting quote from Richard Saperstein, chief investment officer at Treasury Partners. “The next six weeks tend to be seasonally weak for stocks, which is an additional worry for a stock market that is already facing elevated valuations and a lack of near-term upside catalysts”.


Interesting “notes”: Moderna (MRNA) tanks as review argues booster might not be needed …

  • An article in the Lancet suggested that a booster shot wouldn't be necessary for most people after a review of data from clinical trials, as well as efficacy in the real world

Endpoints News @endpts

Fourth boy dies in Astellas-Audentes gene therapy trial, raising fresh fears for the field


If you didn’t remember what happen at Monday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:


  • September, 1 holiday, 3 positive and 5 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

Q2/21 Earnings releases …  … to date:


Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?

Biostage (BSTG) closed up =$0.04 with 26,150 shares traded following Friday’s -$0.19 to $3.79 with 22,124 shares traded, Thursday’s +$0.66 to $3.98 with 6,062 shares traded, Wednesday’s +$0.57 to $3.32 with 7,833 shares traded and last Tuesday’s -$0.75 to $2.75 with 6,705 shares traded

Question#1: Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping – NO clinical trial after a 1.5-year-old IND?

Questiob#2: WHAT is the end game of “pumping” the share price as the float is MINIMAL compared to the ever-OUTSTANDING shares? 

WHY do I keep analyzing/commenting negatively on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!


Pre-open Indications:  who and what’s lookin’ which way …

Maintaining BUY:

Intellia Therapeutics (NTLA) closed down again -$6.35 after Friday’s -$0.14, Thursday’s +$0.02, Wednesday’s -$3.36 after being down Tuesday -$13.53 to $163.25 with a positive +$1.68 or +1.09% pre-market indication,

CRISPR Therapeutics (CRSP) closed down Monday again -$2.74 after Friday’s -$0.72, Thursday’s +$2.20, Wednesday’s -$1.25 after being down last Tuesday-$1.45 to $120.51 and has a positive +$0.29 or +0.25% pre-market indication,

Editas Medicine (EDIT) closed down -$3.14 to $62.96 following Friday’s +$1.65, Thursday’s +$0.13, Wednesday’s -$2.41 and last Tuesday’s -$1.52 to $66.73 and has a positive +$0.54 or +0.86% pre-market indication,


SELL i.e., SKIM:

Regenxbio (RGNX) stock had “rocketed” +$10.32 or +31.20 after announcing an AbbVie eye-disease deal and seems to track down ward -$0.40 or -0.92%


The BOTTOM LINE: I keep reinforcing the theme that increased stock market volatility suppresses the stem, cell and gene therapy sector; yet the more oversold – the greater the capacity to selectively … rebound as an avenue to profiting.

I maintain, the recent stem, cell and gene therapy sector investors should be a bit more defensive, limiting new buys and perhaps curtailing overexposure.

Or it could say buying opportunities are here today and maybe tomorrow but G O N E soon!

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.